1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 13 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironmentHewett, D.; Vandyke, K.; Lawrence, D.; Friend, N.; Noll, J.; Geoghegan, J.; Croucher, P.; Zannettino, A.
2017HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1Vandyke, K.; Zeissig, M.; Hewett, D.; Martin, S.; Mrozik, K.; Cheong, C.; Diamond, P.; To, L.; Gronthos, S.; Peet, D.; Croucher, P.; Zannettino, A.
2017Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stressWallington-Beddoe, C.; Bennett, M.; Vandyke, K.; Davies, L.; Zebol, J.; Moretti, P.; Pitman, M.; Hewett, D.; Zannettino, A.; Pitson, S.
2015Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivoCheong, C.; Chow, A.; Fitter, S.; Hewett, D.; Martin, S.; Williams, S.; To, L.; Zannettino, A.; Vandyke, K.
2010The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivoVandyke, K.; Dewar, A.; Diamond, P.; Fitter, S.; Schultz, C.; Sims, N.; Zannettino, A.
2015Therapeutic targeting of N-cadherin is an effective treatment for multiple myelomaMrozik, K.; Cheong, C.; Hewett, D.; Chow, A.; Blaschuk, O.; Zannettino, A.; Vandyke, K.
2013Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myelomaVandyke, K.; Chow, A.; Williams, S.; To, L.; Zannettino, A.
2011The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferationVandyke, K.; Fitter, S.; Zannettino, A.
2010Dysregulation of bone remodeling by imatinib mesylateVandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.

Discover